Acadia Pharmaceuticals' dementia-related psychosis trial offers new hope to patients diagnosed with Alzheimer's disease. Also, results from a lung cancer trial just strengthened Eli Lilly's leadership in precision medicine.
Stocks: ACAD, LLY
This episode could use a review! Have anything to say about it? Share your thoughts using the button below.Submit Review